A Phase 1 interventional study of PF-08161842 and Placebo for PF-08161842 in Alzheimer Disease, sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Alzheimer Disease by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Pfizer.
Among the 101 studies in Alzheimer Disease by Pfizer, this one is the 26th largest by planned enrollment of the 94 interventional ones that give a count, is the only one that started in 2026, is one of 52 in phase 1, and was the 101st registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →1 of the 101 studies in Alzheimer Disease by Pfizer is open now.
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 27 · Phase 3 17
First in 1999; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 98 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 56 across the 94 interventional studies, 370 across the 5 observational. Of the 99 that completed or were terminated, 40 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Alzheimer Disease by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07897708PfizerA Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults | 2027-03-17 |
Add it to your calendar (.ics) → With an account.
Among the 101 studies in Alzheimer Disease by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08161842) and how it is processed by the body. This is the first time PF-08161842 will be given to people.
This study is seeking healthy adults:
Participants will receive either PF-08161842 tablets or matching placebo tablets. Placebo tablets do not contain active medicine. In some study groups, participants will receive a single dose of study medicine. In other study groups, they will receive the study medicine for 14 days. The tablets will be taken by mouth at the study clinic.
The investigators will compare the experiences of people receiving the study medicine with those of people who do not. This will help researchers determine if PF-08161842 is safe and how it affects the body.
Participants will stay at the study clinic for several days so the study team can closely monitor their health. The study will include physical examinations, checks of blood pressure, heart rate, temperature, and breathing. It will also include blood and urine samples and heart tracing tests (ECGs). Researchers will assess how the body processes the study medicine. Some participants will also have lumbar punctures (spinal taps) to collect small samples of fluid from around the brain and spinal cord. The study team will monitor participants for any reactions throughout the study.
For people receiving a single dose, the study will last for about 9 weeks. For those receiving multiple doses the study will last for about 11 weeks. This includes screening, study visits, clinic stay, and follow-up contact after the last dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive PF-08161842 or matching placebo as a single dose on Day 1.
Drug: PF-08161842 · Drug: Placebo for PF-08161842
Participants will receive doses of PF-08161842 or matching placebo from Day 1 through Day 14.
Drug: PF-08161842 · Drug: Placebo for PF-08161842
Oral tablet (Parts A and B).
Matching placebo tablet (Parts A and B).
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Serious Adverse Events (SAEs)
Time frame: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Laboratory Abnormalities
Time frame: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Vital Signs Abnormalities
Time frame: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
Time frame: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Columbia-Suicidality Severity Rating Scale (C-SSRS)
Time frame: From first dose through approximately 28 to 35 days after the last dose
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)
Time frame: Part A only: Up to Day 5
Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)
Time frame: Part B only: Up to Day 17
Maximum Observed Plasma Concentration (Cmax)
Time frame: Part A: Up to Day 5 Part B: Up to Day 17
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Part A: Up to Day 5 Part B: Up to Day 17
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) if data permit
Time frame: Part A only: Up to Day 5
Plasma Decay Half-life (t1/2) if data permit
Time frame: Part A only: Up to Day 5
Cerebrospinal Fluid (CSF) Concentration of PF-08161842
Time frame: Part A: At day 2 post dose Part B: At day 15 post dose
No study locations are listed for this record.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 4 months is below that.
Counting every sponsor, half of 234 studies reached it within 17 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.